Targeted Therapy: 720 Real Stories

720 stories match targeted therapy. 488 of them mention chemotherapy.

Michelle, who was diagnosed with Stage IV Colorectal CancerColorectal Cancer

Stage IV Colorectal Cancer: Michelle's Patient Story

Patient Info: Michelle Cappel, Female, 40s | Stage IV

Metastatic Site: Leg/femoral nerve area

As of July 2023, Michelle was living with recurrent Stage IV colorectal cancer after prior NED, leg/femoral-nerve recurrence, radiation, surgery with clear margins, and ongoing surveillance.

The Patient Story
OutcomeLiving With Cancer
A patient, who was diagnosed with Lung AdenocarcinomaLung Cancer

MET-mutated lung cancer: testing savolitinib before surgery — Case 1

Patient Info: Anonymized, Male, 70+

Biomarkers: MET exon 14 skipping mutation

The tumour shrank by 82%; surgery found 5% viable residual tumour and no involved lymph nodes, with postoperative stage ypT2aN0M0. He continued savolitinib without serious adverse effects.

PubMed Central
OutcomeResponding Well
A patient, who was diagnosed with Lung AdenocarcinomaLung Cancer

MET-mutated lung cancer: testing savolitinib before surgery — Case 2

Patient Info: Anonymized, Female, 60s

Biomarkers: MET exon 14 skipping mutation; PD-L1 expression 75%

Savolitinib produced approximately 72% tumour shrinkage. Surgery found 30% viable residual tumour, negative lymph nodes and ypT1bN0M0 disease; she recovered without complications and continued savolitinib.

PubMed Central
OutcomeResponding Well
A patient, who was diagnosed with Stage IV Lung AdenocarcinomaLung Cancer

MET-mutated lung cancer: testing savolitinib before surgery

Patient Info: Anonymized, Male, 60s | Stage IV

Biomarkers: MET exon 14 skipping, TP53 and BRAF mutations; PD-L1 expression 5%

Metastatic Site: pleura; mediastinal lymph node

Savolitinib produced a partial radiological response, but surgery confirmed persistent pleural and mediastinal nodal metastases with ypStage IVA disease. He recovered and continued adjuvant savolitinib.

PubMed Central
OutcomeIn Treatment
Jason, who was diagnosed with Stage IV Colorectal CancerColorectal Cancer

My Stage 4 Colorectal Cancer Story: How I Never Lost Hope

Patient Info: Jason Randall, Male | Stage IV

Metastatic Site: Liver; lungs; bone/sacrum

As of June 2023, Jason had a negative Signatera test, CT scans showing 9 months with no evidence of disease, and about 2.5 years off chemotherapy after Stage IV colorectal cancer treatment and lung ablation.

The Patient Story
OutcomeCancer-Free / NED
A patient, who was diagnosed with Stage IV Lung AdenocarcinomaLung Cancer

Lung cancer recurrence in the thyroid, initially mistaken for thyroid cancer

Patient Info: Anonymized, Male | Stage IV

Biomarkers: EGFR exon 19 deletion; TTF-1-positive; Napsin A-positive; PAX8-negative; thyroglobulin staining limited to tumour cells adjacent to normal thyroid tissue

Metastatic Site: thyroid; cervical lymph nodes

After starting osimertinib for EGFR exon 19-deleted recurrent lung adenocarcinoma, he was disease free 5 months after thyroid surgery.

PubMed Central
OutcomeCancer-Free / NED
Elle, who was diagnosed with Stage I Ovarian CancerOvarian Cancer

Stage I Ovarian Cancer: Elle's Patient Story

Patient Info: Elle Simone Scott, Female, Under 40 | Stage I

Living with recurrent ovarian cancer for more than 6 years after her September 2016 diagnosis, with an active clinical trial slowing progression at the May 2023 publication.

Dana-Farber
OutcomeLiving With Cancer
A patient, who was diagnosed with Stage IV Ovarian AdenocarcinomaOvarian Cancer

Stage IV Ovarian Cancer Complicated by Anti-Yo Cerebellar Degeneration

Patient Info: Anonymized, Female | Stage IV

Biomarkers: CA-125: 1767 kU/L; anti-Yo antibodies positive in serum and cerebrospinal fluid

Her anti-Yo paraneoplastic cerebellar degeneration progressed despite methylprednisolone and plasma exchange. Care became palliative, and she died 2 months after hospital admission.

PubMed Central
OutcomeIn Memory
Abigail, who was diagnosed with Stage IV Breast CancerBreast Cancer

Stage IV HR-Positive Breast Cancer: Abigail's Patient Story

Patient Info: Abigail Myers, female, Under 40 | Stage IV

Biomarkers: ER-positive, PR-positive, HER2-positive

Metastatic Site: bones, brain

Abigail continued living with Stage IV metastatic breast cancer after about 8 years of multiple treatment lines, including therapy for bone and brain metastases.

Dana-Farber
OutcomeLiving With Cancer
A patient, who was diagnosed with Stage IV Invasive Ductal CarcinomaBreast Cancer

Chemotherapy complication: methotrexate absorbed into the bloodstream after spinal injection

Patient Info: Anonymized, Female | Stage IV

Biomarkers: ER-positive; PR-positive; HER2-negative; Oncotype DX Recurrence Score 20

Metastatic Site: leptomeninges / central nervous system; brain

Five months after leptomeningeal carcinomatosis was recognised, she developed a new 2 cm brain lesion and neurological decline. Her family chose supportive care, and she died 10 days after transfer to inpatient hospice.

PubMed Central
OutcomeIn Memory
A patient, who was diagnosed with Stage IV Invasive Lobular CarcinomaBreast Cancer

Breast cancer that spread to the thymus gland

Patient Info: Anonymized, Female | Stage IV

Biomarkers: Oestrogen receptor-positive; progesterone receptor-positive; HER2-negative

Metastatic Site: thymus

She had a good response after 4 cycles of abemaciclib, anastrozole and goserelin and continued endocrine treatment with surveillance of the opposite breast.

PubMed Central
OutcomeResponding Well
Tiffany, who was diagnosed with Stage IV Non-Small Cell Lung CancerLung Cancer

Stage IV EGFR Non-Small Cell Lung Cancer: Tiffany's Patient Story

Patient Info: Tiffany, Female | Stage IV

Biomarkers: EGFR mutation

Metastatic Site: Bone: pelvis, right femur, cervical spine

As of March 2023, Tiffany had benefited from Tagrisso plus Cyramza, but later CT findings suggested worsening disease and she had started a new early-stage clinical trial with results pending.

The Patient Story
OutcomeSetback / Progression
A patient, who was diagnosed with Stage III Ovarian CancerOvarian Cancer

Stage IIIC Ovarian Cancer Found During Preoperative Screening

Patient Info: Anonymized, Female | Stage III

Biomarkers: BRCA1 pathogenic variant on homologous recombination deficiency testing; germline BRCA1 pathogenic variant

At approximately 1 year after surgery, she was alive without evidence of recurrence while continuing olaparib and bevacizumab maintenance therapy.

PubMed Central
OutcomeCare Ongoing
A patient, who was diagnosed with Stage II Invasive Ductal CarcinomaBreast Cancer

HER2-positive breast cancer on hemodialysis: partial response to T-DM1 then no metabolically active disease

Patient Info: Anonymized, Female, 60s | Stage II

Biomarkers: Hormone receptor-positive; HER2/neu-positive; E-cadherin-positive; Ki-67 55-60%; luminal B type

As of March 2023, after 12 total cycles of T-DM1 and modified radical mastectomy, PET-CT showed no metabolically active disease, and she continued endocrine therapy and dialysis.

PubMed Central
OutcomeCancer-Free / NED
Langley, who was diagnosed with Stage IV Invasive Ductal CarcinomaBreast Cancer

Stage IV BRCA Invasive Ductal Carcinoma: Langley's Patient Story

Patient Info: Langley Perer, female, Under 40 | Stage IV

Biomarkers: inherited BRCA mutation

Metastatic Site: brain, bones, leptomeninges

After 1 year on a PARP inhibitor, Langley’s metastatic breast cancer remained in check without progression and some lesions had begun to shrink.

Dana-Farber
OutcomeResponding Well
Lanie, who was diagnosed with Stage II Invasive Ductal CarcinomaBreast Cancer

Stage II HER2-Positive Invasive Ductal Carcinoma: Lanie's Patient Story

Patient Info: Lanie Jones, Female, Under 40 | Stage II

Biomarkers: HER2-positive; Li-Fraumeni syndrome / TP53 mutation; BRCA-negative

As of January 2023, Lanie was living with Li-Fraumeni syndrome after 5 cancer diagnoses and was on lifelong maintenance chemotherapy while advocating for genetic testing and specialized surveillance.

The Patient Story
OutcomeCare Ongoing
Anna, who was diagnosed with Stage IV Breast CancerBreast Cancer

Stage IV Breast Cancer: Anna's Patient Story

Patient Info: Anna, Female, 60s | Stage IV

As of 2023, Anna was living with Stage IV breast cancer and receiving treatment that included lumpectomy surgery, hormone therapy, and targeted therapy as her plan.

Our Cancer Stories
OutcomeLiving With Cancer
Anne, who was diagnosed with Stage II Breast CancerBreast Cancer

Stage II Breast Cancer: Anne's Patient Story

Patient Info: Anne, Female, 50s | Stage II

As of 2023, Anne was receiving/continuing care for Stage II breast cancer after lumpectomy, paclitaxel chemotherapy, radiation therapy, and a targeted-therapy plan reduced to 9 rounds by insurance coverage.

Our Cancer Stories
OutcomeCare Ongoing
Rose, who was diagnosed with Stage II Breast CancerBreast Cancer

Stage II Breast Cancer: Rose's Patient Story

Patient Info: Rose | Stage II

Rose remains on radiotherapy, hormone therapy and targeted therapy while continuing to live with concerns about recurrence and metastasis.

Our Cancer Stories
OutcomeCare Ongoing
Hu, who was diagnosed with Stage I Breast CancerBreast Cancer

Stage I Breast Cancer: Hu's Patient Story

Patient Info: Hu Jia, Female | Stage I

As of 2023, Hu Jia was in treatment for Stage I breast cancer after choosing a modified plan that excluded lymphadenectomy, while anticipating future medication costs and focusing on diet, art, reflection, and emotional resilience.

Our Cancer Stories
OutcomeCare Ongoing
Jamie, who was diagnosed with Stage II Breast CancerBreast Cancer

Stage II Breast Cancer: Jamie's Patient Story

Patient Info: Jamie, Female, 40s | Stage II

Jamie was newly diagnosed with Stage II breast cancer in 2023 and had not yet started treatment; her plan included mastectomy, chemotherapy, radiation therapy, and targeted therapy.

Our Cancer Stories
OutcomeCare Ongoing
Maeve, who was diagnosed with Breast CancerBreast Cancer

Breast Cancer: Maeve's Patient Story

Patient Info: Maeve

Maeve had undergone lumpectomy, lymph-node surgery, chemotherapy, radiation, and targeted therapy and was focused on returning to work and being present for her family.

Our Cancer Stories
OutcomeNot reported